HepQuant is a privately-held company with unique, patented and patent-pending technology for evaluating the liver in patients with chronic liver disease.
The company’s products are investigational combination drug / diagnostic devices and have not yet been evaluated or approved by the US Food and Drug Administration (FDA) for commercial sale. They are currently available for investigational use via the FDA IDE application process.
HepQuant has partnered with a College of American Pathologists (CAP) / Clinical Laboratory Improvement Amendments (CLIA)–certified laboratory.
We are headquartered at 8110 E. Union Ave, Suite 750, Denver, CO 80237. Phone: (303) 923-2242